Prism Medico reports mixed financial performance

Prism Medico & Pharmacy, a microcap healthcare services company, has recently announced its financial results for the quarter ended September 2023. The company reported a 44.44% growth in standalone net profit compared to the previous quarter, which had a negative growth of 280.00%. The operating profit (PBDIT) also showed a positive growth of 30.00% in the same period, as opposed to a negative growth of 600.00% in the previous quarter.

However, the company's net sales remained flat in the last few periods and there was no interest income reported. The operating profit margin (excluding other income) also saw a decline from the previous quarter.

Despite the mixed financial performance, Prism Medico's overall score has improved from -5 to 0 in the last three months. The company's operating cash flow has been consistently strong, with the highest amount of Rs 2.95 Cr generated in the last three years.

On the other hand, the debtors turnover ratio has been at its lowest in the last five half-yearly periods, indicating a slower pace in settling debts. This is an area that the company may need to focus on in the future.

MarketsMOJO has given a 'Strong Sell' call for Prism Medico's stock based on its financial results for the quarter ended September 2023. However, it is important to note that this is not a recommendation and should not be considered as such.

Overall, Prism Medico's financial performance for the quarter ended September 2023 has been neutral, with some positive and negative aspects. Investors and stakeholders may want to keep an eye on the company's future financial results to make informed decisions.